Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C.

摘要: Producing effective therapeutic vaccines has proved much more difficult and challenging than developing cancer preventive vaccines. Despite huge research in the area of immunology, FDA/EMEA have not approved any type treatment vaccine so far. More 99% cervical cancers detectable amounts human papillomavirus (HPV) DNA. Integration high-risk HPV into host cell genome is followed by continual expression E6 E7 oncoproteins, making them excellent targets for which could be used high grade precancerous (CIN) lesions or invasive prevention recurrence. Therapeutic been extensively studied. Strategies were vaccination with peptides proteins, alone pulsed dendritic cells, DNA vaccines, virus-like particles viral bacterial vectors. Lovaxin-C a recombinant live-attenuated Listeria monocytogenes (Lm) that secretes antigen HPV-16 fused to non-hemolytic listeriolysin O protein. In phase I study was administered advanced patients refractory existing therapies. The dose-limiting toxicity hypotension flue-like syndrome. There no serious adverse events. Specific T-cell response detected as well clinical Lovaxin-C. Several other are development most studies specific immunological responses seen. Efficacious should expected near future.